SCHEMBL2493582

SCHEMBL2493582

O=C1NC(=S)N(c2cccc(Cl)c2)C(=O)C1=Cc1ccco1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 11/20 0.77
KMT2A Q03164 11/20 0.77
BLM P54132 8/20 0.77
POLB P06746 8/20 0.77
USP2 O75604 4/20 0.77
GAA P10253 4/20 0.77
DNMT1 P26358 2/20 0.77
NSD2 O96028 1/20 0.71
CTDSP1 Q9GZU7 1/20 0.71
PPP1CA P62136 1/20 0.69
CACNA1B Q00975 1/20 0.69
APBA1 Q02410 1/20 0.69
ALPL P05186 1/20 0.65
ALPI P09923 1/20 0.65
ALPG P10696 1/20 0.65
GRK2 P25098 1/20 0.65
GALK1 P51570 1/20 0.61
KCNH2 Q12809 1/20 0.61
ITGA4 P13612 1/20 0.60
ITGB7 P26010 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14777540 1.00 MEN1 (0.77) MEN1KMT2ABLMPOLBUSP2
SCHEMBL2493268 0.88 MEN1 (0.80) MEN1KMT2ABLMPOLBUSP2
SCHEMBL2493271 0.88 MEN1 (0.80) MEN1KMT2ABLMPOLBUSP2
SCHEMBL29504051 0.88 MEN1 (0.75) MEN1KMT2ABLMPOLBUSP2
SCHEMBL30457953 0.88 MEN1 (0.78) MEN1KMT2ABLMPOLBUSP2
SCHEMBL29504050 0.88 MEN1 (0.75) MEN1KMT2ABLMPOLBUSP2
SCHEMBL22396433 0.88 MEN1 (0.75) MEN1KMT2ABLMPOLBUSP2
SCHEMBL25633644 0.88 MEN1 (0.78) MEN1KMT2ABLMPOLBUSP2
SCHEMBL14444644 0.87 MEN1 (1.00) MEN1KMT2ABLMPOLBUSP2
SCHEMBL30457527 0.87 MEN1 (1.00) MEN1KMT2ABLMPOLBUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10098887-B2 Antiviral compounds and methods of use thereof TRANA DISCOVERY, INC. (US) 2018-10-16 US disclosed
US-20160129006-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY INC (US) 2016-05-12 US disclosed
US-9173886-B2 Antiviral compounds and methods of use thereof TRANA DISCOVERY, INC. (US) 2015-11-03 US disclosed
US-20130071353-A1 Antiviral Compounds and Methods of Use Thereof TRANA DISCOVERY, INC (US) 2013-03-21 US disclosed
WO-2011113060-A2 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY, INC. (US) 2011-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10098887-B2 Antiviral compounds and methods of use thereof TYMP, MAVS, ZC3HAV1 MEN1 4495/4885KMT2A 2800/4885BLM 1967/4885
US-20160129006-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TYMP, MAVS, ZC3HAV1 MEN1 4495/4885KMT2A 2800/4885BLM 1967/4885
US-20130071353-A1 Antiviral Compounds and Methods of Use Thereof TYMP, MAVS, ZC3HAV1 MEN1 4495/4885KMT2A 2800/4885BLM 1967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.